Jan A. Saaiman

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 112 citations · Full text

Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention

Marc Cohen, Deepak L. Bhatt, John H. Alexander et al. · Circulation · 2007 · 99 citations · Full text

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 32 citations · Full text

Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial

Marshall Heradien, Felix Mahfoud, Christeman Greyling et al. · Heart Rhythm · 2022 · 27 citations

Hypertension, Cardiovascular Disease, Medicine +13

Endovascular aortic aneurysm repair by a multidisciplinary team: lessons learned and six-year clinical update.

D. F. Du Toit, Jan A. Saaiman, J P Carpenter et al. · PubMed · 2005 · 15 citations